Arkolith/Insider Trading/SKYE/Form 4

Smith Karen L.

DirectorSkye Bioscience, Inc. (SKYE) · full profile →Form 4 · filed Jul 5, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 2, 2024Grant(A)40K—$040K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001516551-24-000068) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML